A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Inclusion Criteria: * Diagnosis of histologically confirmed follicular lymphoma with detectable BCL2-t or mantle cell lymphoma with presence of cyclin D1 overexpression (can be newly diagnosed or relapsed) * Measurable disease (At least one tumor mass \> 1 cm in diameter) * Low tumor burden: 1. No individual masses larger than 6 cm in diameter 2. No more than three masses larger than 3 cm in diameter 3. No lymphoma-related symptoms * The treating physician does not feel that treatment with chemotherapy is indicated * ECOG performance status of 0-2 * Adequate bone marrow and end organ function: i. ANC≥1500/mm3, hemoglobin≥10 g/dL, platelet≥100/mm3 ii. CrCL≥50 mL/min by Cockcroff Gault calculation Exclusion Criteria: * Indication for treatment of lymphoma including large tumor burden or symptomatic disease * Pregnancy or men whose female partners are pregnant * Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment) * Significant or unstable cardiac disease * Hemoglobinopathy (thalassemia or sickle cell disease)